Design Therapeutics Stock Performance
DSGN Stock | USD 4.03 0.12 3.07% |
On a scale of 0 to 100, Design Therapeutics holds a performance score of 12. The firm shows a Beta (market volatility) of 2.66, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Design Therapeutics will likely underperform. Please check Design Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Design Therapeutics' price patterns will revert.
Risk-Adjusted Performance
12 of 100
Low | High |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 9.52 | Five Day Return 18.84 | Year To Date Return 53.94 | Ten Year Return (90.58) | All Time Return (90.58) |
1 | Acquisition by Sean Jeffries of 350000 shares of Design Therapeutics subject to Rule 16b-3 | 01/05/2024 |
2 | Design Therapeutics, Inc. Given Average Rating of Hold by Analysts - MarketBeat | 01/12/2024 |
3 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc ... - The Globe and Mail | 02/15/2024 |
4 | Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs ... - Marketscreener.com | 02/23/2024 |
5 | RTW Investments LP Boosts Stock Position in Design Therapeutics, Inc. - MarketBeat | 03/06/2024 |
6 | Disposition of 175000 shares by Kim Jae B. of Design Therapeutics at 2.54 subject to Rule 16b-3 | 03/13/2024 |
7 | Acquisition by Xu Stella of 44398 shares of Design Therapeutics subject to Rule 16b-3 | 03/14/2024 |
8 | Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results | 03/19/2024 |
9 | Design Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 03/20/2024 |
10 | Acquisition by Schmid John P. of 9156 shares of Design Therapeutics at 3.6187 subject to Rule 16b-3 | 03/22/2024 |
11 | Acquisition by Berger Heather A. of 1300 shares of Design Therapeutics at 3.7429 subject to Rule 16b-3 | 03/25/2024 |
12 | Independent Director of Design Therapeutics Picks Up 88 percent More Stock | 03/27/2024 |
Begin Period Cash Flow | 26.5 M |
Design |
Design Therapeutics Relative Risk vs. Return Landscape
If you would invest 265.00 in Design Therapeutics on December 29, 2023 and sell it today you would earn a total of 126.00 from holding Design Therapeutics or generate 47.55% return on investment over 90 days. Design Therapeutics is currently generating 0.7381% in daily expected returns and assumes 4.5555% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Design, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Design Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Design Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Design Therapeutics, and traders can use it to determine the average amount a Design Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.162
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | DSGN | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
4.56 actual daily | 40 60% of assets are more volatile |
Expected Return
0.74 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Design Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Design Therapeutics by adding it to a well-diversified portfolio.
Design Therapeutics Fundamentals Growth
Design Stock prices reflect investors' perceptions of the future prospects and financial health of Design Therapeutics, and Design Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Design Stock performance.
Return On Equity | -0.22 | ||||
Return On Asset | -0.15 | ||||
Current Valuation | (76.78 M) | ||||
Shares Outstanding | 56.49 M | ||||
Price To Book | 0.73 X | ||||
Price To Sales | 22,642 X | ||||
Gross Profit | (48.61 M) | ||||
EBITDA | (78.19 M) | ||||
Net Income | (66.86 M) | ||||
Cash Per Share | 6.45 X | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 48.96 X | ||||
Cash Flow From Operations | (58.56 M) | ||||
Earnings Per Share | (1.19) X | ||||
Total Asset | 289.64 M | ||||
Retained Earnings | (177.63 M) | ||||
About Design Therapeutics Performance
To evaluate Design Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Design Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Design Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Design Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Design's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.28) | (0.27) | |
Return On Assets | (0.23) | (0.24) | |
Return On Equity | (0.24) | (0.23) |
Things to note about Design Therapeutics performance evaluation
Checking the ongoing alerts about Design Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Design Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Design Therapeutics appears to be risky and price may revert if volatility continues | |
Net Loss for the year was (66.86 M) with loss before overhead, payroll, taxes, and interest of (48.61 M). | |
Design Therapeutics currently holds about 359.38 M in cash with (58.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Design Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Independent Director of Design Therapeutics Picks Up 88 percent More Stock |
- Analyzing Design Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Design Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Design Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Design Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Design Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Design Therapeutics' stock. These opinions can provide insight into Design Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.